CytoDyn (OTCQB: CYDY) has announced that leronlimab will be evaluated in two new metastatic triple-negative breast cancer regimens within clinical research organization Quantum Leap Healthcare Collaborative’s (QLHC) PRE-I-SPY Phase 1-1b platform study, with enrollment expected to begin shortly.
According to CytoDyn, both studies are designed to assess safety and tolerability in earlier-line metastatic treatment settings while exploring preliminary signals of clinical activity. The two studies will evaluate leronlimab in distinct immunotherapy-based combinations, each incorporating a PD-1 inhibitor.
In a statement, Jacob Lalezari, MD, head of research and translational sciences at CytoDyn, commented, “These studies represent an important opportunity to further investigate the potential of CCR5 inhibition as part of combination treatment strategies for patients with metastatic triple-negative breast cancer. By evaluating leronlimab alongside different immunotherapy-based regimens and incorporating exploratory biomarker analyses, we hope to gain a better understanding of its potential role in modulating the tumor microenvironment and informing future treatment approaches for patients with this aggressive disease.”
